> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Quanterix’s Alzheimer’s Test Growth Runs Ahead Of Sales As Volume Doubles From Prior Quarter
- URL: https://www.bullished.co/quanterixs-alzheimers-test-growth-runs-ahead-of-sales-as-volume-doubles-from-prior-quarter-bb5a3162/
- Published: 2026-11-09T14:35:52.000Z
- Updated: 2026-11-09T14:35:52.000Z
- Description: Diagnostic-partner revenue fell to $1.2 million as recurring testing sales failed to offset fewer instrument placements.
- Author: Matteo Parrino
- Tags: Earnings, QTRX, Industry: Healthcare

[Quanterix](https://www.bullished.co/tag/qtrx/), which sells tools for detecting tiny amounts of proteins and analyzing tissue samples, doubled Alzheimer’s test volume from the prior quarter, but the business’s revenue remains “still relatively immaterial,” Chief Financial Officer Jason Faessler said on Monday’s earnings call. President and CEO Everett Cunningham said testing growth came “off a low base,” with most tests billed to clients.

## More Tests, Smaller Partner Revenue

The gap between testing activity and sales drew a question from a Canaccord Genuity analyst: Had revenue doubled along with volume, and how was the test gaining customers without FDA clearance? Faessler said management would hold off on releasing testing revenue figures.

The broader diagnostic-partner business generated $1.2 million in the third quarter, down from a year earlier and also lower for the year to date. Fewer instrument placements drove the decline; recurring laboratory testing revenue had yet to make up the difference.

Cunningham pointed to dedicated sales staff and distribution partners as the routes to expansion. The diagnostics team now has approximately 20 people under Jeff Albrecht, its general manager, who came from Quest Diagnostics.

Quanterix signed partnerships with Sherman Abrams in the New York–New Jersey tri-state area and TruPath in Mississippi, with the latter spanning over 14 states. Both relationships are expected to become operational soon. Management is also discussing additional reference-laboratory partnerships, including international relationships.

## Florida Coverage And An FDA Review

Florida House Bill 885 directed the Florida Agency for Healthcare Administration to cover Alzheimer’s blood-biomarker testing when medical necessity criteria are met. Coverage took effect Sunday, with reimbursement retroactive to July 2026, for a state with over 4 million Medicaid-eligible residents.

Cunningham corrected the reimbursement figure during questions: “I said $480\. It's actually $484.” Quanterix hired a dedicated market-access employee last month and is pursuing coverage through states, federal programs and commercial insurers. Cunningham said he expects other states to enact coverage, while describing pricing and reimbursement discussions as early-stage.

The company’s five-biomarker Alzheimer’s blood test remains under FDA review. Cunningham described discussions with the agency as productive but said management could not predict its timing. Roche and C2N have received approvals, he noted. Quanterix also awaits publication of completed clinical-utility studies from three major health organizations.

Diagnostics sits alongside a research business selling instruments, recurring consumables and test kits, software and service contracts. Its Accelerator Laboratory in Bedford, Massachusetts, provides contract research and clinical testing. The company also intends to expand neurological testing into Parkinson’s disease, Huntington’s disease and traumatic brain injuries.

## Revenue Must Fund The Rebuild

Companywide third-quarter revenue was [$35 million](https://www.businesswire.com/news/home/20261109773090/en/Quanterix-Releases-Financial-Results-for-the-Third-Quarter-of-2026?ref=bullished.co), up 6.3% from the prior quarter but down 13.1% from $40.2 million a year earlier. Spatial consumables reached their second-highest quarterly level. Quanterix narrowed its annual revenue outlook to approximately $142 million–$146 million.

The commercial rebuild includes Jim Gute’s mid-August appointment as chief commercial officer and Dr. Yuri Fesko’s appointment as chief medical officer in September. Management reorganized selling teams around products and added dedicated Accelerator sales staff.

Asked by a TD Cowen analyst about the fourth-quarter outlook, Cunningham called it “not a layup.” Faessler expects Accelerator revenue to step up as bookings turn into billings, alongside higher consumables sales; instrument placements will help determine where results land within the range. Accelerator generated about $2.9 million in the third quarter, and bookings approached twice billings for the second consecutive quarter.

Quanterix used $16.2 million in cash during the quarter and ended it with approximately [$80.7 million](https://www.businesswire.com/news/home/20261109773090/en/Quanterix-Releases-Financial-Results-for-the-Third-Quarter-of-2026?ref=bullished.co). Management expects approximately $70 million in year-end cash and no debt, with full-year adjusted gross margins of 48%–50%.

Faessler reaffirmed the 2027 cash-flow breakeven target, postponed from 2026 last quarter when revenue expectations fell. Revenue growth, he said, remains one of the biggest requirements for reaching it.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Quanterix Releases Financial Results for the Third Quarter of 2026](https://www.businesswire.com/news/home/20261109773090/en/Quanterix-Releases-Financial-Results-for-the-Third-Quarter-of-2026?ref=bullished.co) — businesswire.com

### More on Quanterix

- [Quanterix Returns To Quarterly Sales Growth — But Revenue Still Falls 13% From Last Year](https://www.bullished.co/quanterix-returns-to-quarterly-sales-growth-but-revenue-still-falls-13-from-last-year-99a0e178/)

[All Quanterix (QTRX) coverage →](https://www.bullished.co/tag/qtrx/)